Ralph Weichselbaum to Antibodies, Monoclonal
This is a "connection" page, showing publications Ralph Weichselbaum has written about Antibodies, Monoclonal.
Connection Strength
0.491
-
More on cetuximab in head and neck cancer. N Engl J Med. 2007 Nov 22; 357(21):2201-2; author reply 2202-3.
Score: 0.170
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.109
-
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999 Jul 15; 59(14):3374-8.
Score: 0.095
-
Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1539-48.
Score: 0.052
-
Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 2002 Jan-Feb; 8(1):47-54.
Score: 0.028
-
Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy. Gynecol Oncol. 1990 Sep; 38(3):478-85.
Score: 0.013
-
Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
Score: 0.013
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.011